Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Research Article

Free Access

M1 Protein Allows Group A Streptococcal Survival in Phagocyte Extracellular Traps through Cathelicidin Inhibition

Lauth X.a, f · von Köckritz-Blickwede M.a · McNamara C.W.b · Myskowski S.a · Zinkernagel A.S.a · Beall B.e · Ghosh P.b · Gallo R.L.a, c, f · Nizet V.a, d, g

Author affiliations

Departments of aPediatrics, bChemistry and Biochemistry, and cMedicine, and dSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, Calif., eRespiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Ga., fVeterans Affairs San Diego Healthcare Center and gRady Children’s Hospital, San Diego, Calif., USA

Corresponding Author

Prof. Victor Nizet

Department of Pediatrics and Skaggs School of Pharmacy

and Pharmaceutical Sciences, University of California

9500 Gilman Drive, MC 0687, La Jolla, CA 92093-0687 (USA)

Tel. +1 858 534 7408, Fax +1 858 534 5611, E-Mail vnizet@ucsd.edu

Related Articles for ""

J Innate Immun 2009;1:202–214

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


M1 protein contributes to Group A Streptococcus (GAS) systemic virulence by interfering with phagocytosis and through proinflammatory activities when released from the cell surface. Here we identify a novel role of M1 protein in the stimulation of neutrophil and mast cell extracellular trap formation, yet also subsequent survival of the pathogen within these DNA-based innate defense structures. Targeted mutagenesis and heterologous expression studies demonstrate M1 protein promotes resistance to the human cathelicidin antimicrobial peptide LL-37, an important effector of bacterial killing within such phagocyte extracellular traps. Studies with purified recombinant protein fragments mapped the inhibition of cathelicidin killing to the M1 hypervariable N-terminal domain. A survey of GAS clinical isolates found that strains from patients with necrotizing fasciitis or toxic shock syndrome were significantly more likely to be resistant to cathelicidin than GAS M types not associated with invasive disease; M1 isolates were uniformly resistant. We conclude increased resistance to host cathelicidin and killing within phagocyte extracellular traps contribute to the propensity of M1 GAS strains to produce invasive infections.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: November 27, 2008
Accepted: December 15, 2008
Published online: February 20, 2009
Issue release date: April 2009

Number of Print Pages: 13
Number of Figures: 5
Number of Tables: 0

ISSN: 1662-811X (Print)
eISSN: 1662-8128 (Online)

For additional information: http://www.karger.com/JIN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.